GH Research (GHRS) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $18.15, -3.51% vs the prior close of $18.81.
- Volume 162.60K shares, 0.6x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
GHRS slides 3.5% to $18.15, a 6-month low. Closed at $18.15, -3.51% vs the prior close of $18.81. Day range $18.05–$19.17, opened at $18.92.
GHRS daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — GHRS slides 3.5% to $18.15, a 6-month low
- Closed at $18.15, -3.51% vs the prior close of $18.81. Day range $18.05–$19.17, opened at $18.92.
- Volume was 162.60K shares, 0.6x its 50-day average of 286.57K — lighter than usual.
- Price is -30.3% vs its 50-day average ($26.05) and -14.9% vs its 200-day average ($21.33).
- 52-week range $12.04–$31.44; today's close sits at 31% of that range, 42.3% below the 52-week high.
Oct 15, 2026 — GHRS rises 1.3% to $18.81
- Closed at $18.81, +1.35% vs the prior close of $18.56. Day range $18.48–$19.39, opened at $18.75.
- Volume was 276.70K shares, 1.0x its 50-day average of 285.68K.
- Price is -28.5% vs its 50-day average ($26.30) and -11.7% vs its 200-day average ($21.30).
- 52-week range $12.04–$31.44; today's close sits at 35% of that range, 40.2% below the 52-week high.
Oct 14, 2026 — GHRS dips 1.5% to $18.56, a 3-month low, 3 down days in a row
- Closed at $18.56, -1.54% vs the prior close of $18.85. Day range $18.29–$19.19, opened at $18.64.
- Volume was 304.40K shares, 1.0x its 50-day average of 292.23K.
- Price is -30.0% vs its 50-day average ($26.51) and -12.8% vs its 200-day average ($21.27).
- 52-week range $12.04–$31.44; today's close sits at 34% of that range, 41.0% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — GHRS slides 5.8% to $18.85, a 3-month low
- Closed at $18.85, -5.84% vs the prior close of $20.02. Day range $18.72–$19.90, opened at $19.88.
- Volume was 425.50K shares, 1.5x its 50-day average of 288.55K.
- Price is -29.5% vs its 50-day average ($26.72) and -11.3% vs its 200-day average ($21.24).
- 52-week range $12.04–$31.44; today's close sits at 35% of that range, 40.0% below the 52-week high.
Oct 12, 2026 — GHRS slides 5.2% to $20.02, a 3-month low
- Closed at $20.02, -5.16% vs the prior close of $21.11. Day range $20.01–$21.23, opened at $21.05.
- Volume was 229.70K shares, 0.8x its 50-day average of 287.52K.
- Price is -25.6% vs its 50-day average ($26.91) and -5.6% vs its 200-day average ($21.21).
- 52-week range $12.04–$31.44; today's close sits at 41% of that range, 36.3% below the 52-week high.
Oct 9, 2026 — GHRS jumps 3.2% to $21.11
- Closed at $21.11, +3.23% vs the prior close of $20.45. Day range $20.45–$21.30, opened at $20.66.
- Volume was 146.00K shares, 0.5x its 50-day average of 292.38K — lighter than usual.
- Price is -22.0% vs its 50-day average ($27.07) and -0.3% vs its 200-day average ($21.18).
- 52-week range $12.04–$31.44; today's close sits at 47% of that range, 32.9% below the 52-week high.
- SEC filings that day: 6-K.
Oct 8, 2026 — GHRS dips 2.9% to $20.45, a 3-month low, 4 down days in a row
- Closed at $20.45, -2.90% vs the prior close of $21.06. Day range $19.87–$21.07, opened at $20.94.
- Volume was 332.20K shares, 1.1x its 50-day average of 290.45K.
- Price is -24.9% vs its 50-day average ($27.21) and -3.2% vs its 200-day average ($21.14).
- 52-week range $12.04–$31.44; today's close sits at 43% of that range, 35.0% below the 52-week high.
- That makes 4 straight losses.
Oct 7, 2026 — GHRS dips 2.1% to $21.06, a 3-month low, 3 down days in a row
- Closed at $21.06, -2.14% vs the prior close of $21.52. Day range $21.00–$22.17, opened at $21.39.
- Volume was 304.60K shares, 1.1x its 50-day average of 288.40K.
- Price is -23.0% vs its 50-day average ($27.36) and -0.2% vs its 200-day average ($21.10).
- 52-week range $12.04–$31.44; today's close sits at 46% of that range, 33.0% below the 52-week high.
- That makes 3 straight losses.
Oct 6, 2026 — GHRS dips 2.9% to $21.52, a 3-month low
- Closed at $21.52, -2.93% vs the prior close of $22.17. Day range $21.21–$22.27, opened at $22.23.
- Volume was 495.40K shares, 1.7x its 50-day average of 284.09K.
- Price is -21.7% vs its 50-day average ($27.50) and +2.2% vs its 200-day average ($21.06).
- 52-week range $12.04–$31.44; today's close sits at 49% of that range, 31.5% below the 52-week high.
Oct 5, 2026 — GHRS slides 3.4% to $22.17, a 3-month low
- Closed at $22.17, -3.36% vs the prior close of $22.94. Day range $21.86–$23.00, opened at $23.00.
- Volume was 207.00K shares, 0.7x its 50-day average of 283.23K.
- Price is -19.7% vs its 50-day average ($27.63) and +5.5% vs its 200-day average ($21.01).
- 52-week range $12.04–$31.44; today's close sits at 52% of that range, 29.5% below the 52-week high.
Oct 2, 2026 — GHRS rises 0.3% to $22.94
- Closed at $22.94, +0.35% vs the prior close of $22.86. Day range $22.36–$23.12, opened at $23.05.
- Volume was 230.00K shares, 0.8x its 50-day average of 281.50K.
- Price is -17.3% vs its 50-day average ($27.73) and +9.4% vs its 200-day average ($20.96).
- 52-week range $12.04–$31.44; today's close sits at 56% of that range, 27.0% below the 52-week high.
GHRS latest news & SEC filings
Every SEC filing by or about GHRS in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 9, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 11, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 6, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Jun 26, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Things to know before you trade GHRS
- How much it moves: over the last 20 sessions the average daily move was 3.17% (largest 6.8%). That is a volatile stock.
- Liquidity: about 325.26K shares (≈$5.90M) trade per day on average.
- 52-week position: $18.15 vs a range of $12.04–$31.44 (31% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 6-K Oct 9, 2026; 6-K Sep 11, 2026; 6-K Aug 6, 2026.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
GHRS market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 18.92 | 19.17 | 18.05 | 18.15 | 162.60K |
| Oct 15, 2026 | 18.75 | 19.39 | 18.48 | 18.81 | 276.70K |
| Oct 14, 2026 | 18.64 | 19.19 | 18.29 | 18.56 | 304.40K |
| Oct 13, 2026 | 19.88 | 19.90 | 18.72 | 18.85 | 425.50K |
| Oct 12, 2026 | 21.05 | 21.23 | 20.01 | 20.02 | 229.70K |
| Oct 9, 2026 | 20.66 | 21.30 | 20.45 | 21.11 | 146.00K |
| Oct 8, 2026 | 20.94 | 21.07 | 19.87 | 20.45 | 332.20K |
| Oct 7, 2026 | 21.39 | 22.17 | 21.00 | 21.06 | 304.60K |
| Oct 6, 2026 | 22.23 | 22.27 | 21.21 | 21.52 | 495.40K |
| Oct 5, 2026 | 23.00 | 23.00 | 21.86 | 22.17 | 207.00K |
| Oct 2, 2026 | 23.05 | 23.12 | 22.36 | 22.94 | 230.00K |
| Oct 1, 2026 | 23.31 | 23.90 | 22.53 | 22.86 | 255.10K |
| Sep 30, 2026 | 24.92 | 24.92 | 23.13 | 23.48 | 384.70K |
| Sep 29, 2026 | 23.39 | 24.99 | 23.12 | 24.67 | 1.13M |
| Sep 28, 2026 | 23.48 | 23.67 | 22.89 | 23.42 | 609.70K |
| Sep 25, 2026 | 24.48 | 24.55 | 23.49 | 23.84 | 180.00K |
| Sep 24, 2026 | 26.10 | 26.10 | 23.43 | 24.45 | 418.20K |
| Sep 23, 2026 | 28.13 | 28.13 | 25.67 | 25.96 | 178.80K |
| Sep 22, 2026 | 28.02 | 28.45 | 27.61 | 27.86 | 101.60K |
| Sep 21, 2026 | 28.48 | 28.50 | 27.76 | 27.93 | 131.10K |
About GH Research
GH Research (GHRS) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in DUBLIN 2, Ireland. State of incorporation: Ireland. Fiscal year ends December 31. SEC CIK 1855129.
GHRS board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Michael Forer | Director | Aug 13, 2026 |
| Dermot John Hanley | Director | Aug 13, 2026 |
| Duncan Moore | Director | Aug 13, 2026 |
| Florian Schonharting | Director | Sep 9, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Aaron Luke Cameron | Chief Operating Officer | Apr 2, 2026 |
| Magnus Clemensen Halle | Managing Director, Ireland | Apr 2, 2026 |
| Julie Ryan | VP, Finance | Apr 2, 2026 |
| Velichka Valcheva | Chief Executive Officer | Apr 2, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
GHRS financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| No annual XBRL figures available (foreign filers often report on Form 20-F). | ||||
Latest balance sheet: total assets $—, total liabilities $—, cash $—.
GHRS earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| No 8-K earnings releases in recent filings. | ||
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on GHRS
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.